Baylor College of Medicine

 

3rd Annual Hematologic Malignancies Symposium
26:33

3rd Annual Hematologic Malignancies Symposium

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Benefit? What Is the Role of MRD? Is Sorafenib a Good Maintenance Choice?

FEATURING Alexander Perl
  • 144 views
  • April 8, 2021
  • 1
07:34

3rd Annual Hematologic Malignancies Symposium

2021 Updates on FLT3m R/R AML: What Is the Current Standard of Care? Early Data Results on Venetoclax + Gilteritinib Combination

FEATURING Alexander Perl
  • 214 views
  • April 8, 2021
  • 1
15:35

3rd Annual Hematologic Malignancies Symposium

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve OS in FLT3m Disease? Are DA+Cytarabine+/-GO Beneficial for EFS in Untreated Patients? Is CPX-351 Better Than SoC Chemo?

FEATURING Gail G. Roboz
  • 126 views
  • April 8, 2021
  • 1
22:10

3rd Annual Hematologic Malignancies Symposium

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Therapy Strategies and Outcomes

FEATURING Courtney D. DiNardo
  • 231 views
  • April 8, 2021
  • 1
26:23

3rd Annual Hematologic Malignancies Symposium

HMA Resistance & Treatment After HMT Failure in MDS: Aza vs. CCR, Induction Chemo, Ven+Aza, Sabatolimab+HMA, Pev+Aza vs. Aza

FEATURING Hetty Carraway
  • 128 views
  • April 7, 2021
  • 1
15:41

3rd Annual Hematologic Malignancies Symposium

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Outcomes, Enasidenib/Ivosidenib, HMA Combinations, Options for Clonal Escape

FEATURING Andrew Wei
  • 415 views
  • April 7, 2021
  • 2